XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of warrant and stock option grants with time-based vesting
   Warrant Grants   Stock Option Grants   Restricted
Stock Units
 
   Number of
shares
subject to
warrants
   Weighted-
average
exercise
price per
share
   Number of
shares
subject to
options
   Weighted-
average
exercise
price per
share
   Number of
shares
subject to
restricted
stock units
 
Balance at December 31, 2020   672,459   $8.09    118,388   $3.25    2,301,053 
Granted   389,344    2.30    
-
    
-
    843,338 
Exercised   
-
    
-
    
-
    
-
    (675,219)
Expired   (11,699)   
-
    
-
    
-
    (150,833)
Balance at September 30, 2021   1,050,104   $2.57    118,388   $3.25    2,318,339 
Exercisable at September 30, 2021   1,050,104   $2.57    118,388   $3.25    1,464,631 

 

Schedule of fair value of the warrants as of original issuance date
    Issuance date  
Risk-free interest rate     0.49 - 0.88 %
Expected dividend yield     - %
Expected volatility     100 %
Term     5 years  
Fair value of common stock     1.95 - 2.24  

 

Schedule of company’s outstanding warrants and options
Warrants Outstanding     Warrants Exercisable  
Exercise Price
Range
    Number Outstanding     Weighted Average
Remaining
Contractual Life
(in years)
    Weighted Average
Exercise Price
    Number Exercisable     Weighted Average
Exercise Price
    Intrinsic Value  
$ 1.79 - $20.90       1,050,104       3.23     $ 2.57     1,050,104     $ 2.57       290,525  
                                                   

 

Options Outstanding     Options Exercisable  
Exercise Price
Range
    Number Outstanding     Weighted Average
Remaining
Contractual Life
(in years)
    Weighted Average
Exercise Price
    Number Exercisable     Weighted Average
Exercise Price
    Intrinsic Value  
$ 2.64 - $28.50       118,388       2.94     $ 3.25     118,388     $ 3.25      
-
 
                                                   

 

Schedule of stock-based compensation expense
    For the
three months ended
    For the
nine months ended
 
    September 30,     September 30,  
    2021     2020     2021     2020  
Stock-based compensation expense   $ 699,084     $ 488,304     $ 1,929,446     $ 2,844,851  
                                 

 

Schedule of stock-based compensation expense categorized by the equity components
   For the
three months ended
   For the
nine months ended
 
   September 30,   September 30, 
   2021   2020   2021   2020 
Common stock  $699,084   $488,304   $1,929,446   $2,844,851 
Total  $699,084   $488,304   $1,929,446   $2,844,851